Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Celgene Licenses Lead Program From Epizyme, Takes Option To Remaining Pipeline

This article was originally published in The Pink Sheet Daily

Executive Summary

Celgene has expanded its footprint in epigenetics, partnering with histone methyltransferase specialist Epizyme to take immediate rights to its preclinical DOT1L program and a three-year extendable option on the rest of the biotech’s pipeline.

You may also be interested in...



For Its Latest Epigenetics Deal, Celgene Takes Option To Buy Acetylon

A $100 million, non-dilutive investment will keep Acetylon off the market, giving Celgene the right to buy it for a minimum of $500 million up-front within a pre-determined time window. For now, Acetylon retains all rights to its pipeline, including Phase Ib multiple myeloma drug ACY-1215.

Epizyme Execs On Company’s IPO, Clinical Progress And Diagnostic Strategy

Epizyme and its partners have moved two programs into the clinic and will start an expansion trial for the DOT1L program later this year. It has also struck deals for companion diagnostics, making steady progress personalized medicine solutions for patients with genetically defined cancers within five years of starting clinical trials. CEO Robert Gould and Exec VP Jason Rhodes take stock of the company’s progress.

With Celgene Deal, Forma Makes First Foray Into Clinical Development

Forma Therapeutics has signed its largest and most ambitious oncology drug-discovery and development collaboration to date, in the exciting but early-stage area of protein homeostasis. Its new partner Celgene is no stranger to making big bets on promising cancer companies.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS074074

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel